References
- Brennan FM, Maini RN, Feldmann M. TNF-a: a pivotal role in rheumatoid arthritis. Br J Rheumatol 1992;31:293–8.
- Elliot MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arhtritis Rheum 1993;36:1681–90.
- Barrera P, Joosten LAB, van de Putte LBA, van Riel PLCM, van der Berg WB. Effects of treatment with fully human anti-tumour necrosis factor-a monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFa in patients with rheumatoid arthritis. Ann Rheum Dis 2001;60: 660–9.
- Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594–602.
- Weyand C, Goronzy J. The molecular basis of rheumatoid arthritis. J Mol Med 1997;75:772–85.
- Bouma G, Crusius JBA, Oudkerk Pool M, Kolkman JJ, Von Blomberg BME, Kostense PJ, et al. Secretion of tumour necrosis factor and lymphotoxin in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996;43:456–63.
- Uglialoro AM, Turbay D, Pesavento PA, Delgado JC, Mckenzie FE, Gribben JG, et al. Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter. Tissue Antigens 1998;52:359–67.
- Wilson AG, di Giovine FS, Blakemore AIF, Duff GW. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by Nco 1 restriction of PCR product. Hum Mol Genet 1992;1:353.
- Danis VA, Millington M, Hyland V, Lawford R, Huang Q, Grennan D. Increased frequency of the uncommon allele of a tumour necrosis factor alpha polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers 1995;12:127–33.
- Cuenca J, Cuchacovich M, Ferreira L, Perez C, Aguirre A, Schiattino I, et al. The -308 polymorphism in the tumor necrosis factor gene promoter region and ex - vivo lipopolysaccharide-induced TNF expression and cytotoxic activity in Chilean patients with rheumatoid arthritis. Rheumatology 2003;42:308–13.
- Padyukov L, Lampa J, Berg L, Harju A, Klareskog L. Association of -308 TNFA and -1082 IL-10 polymorphism with the effect of treatment with soluble TNF receptor in rheumatoid arthritis patients. Immunol Lett 2000;73:A538.
- Kroeger K, Steer J, Joyce D, Abraham L. Effects of stimulus and cell type on the expression of the -308 tumour necrosis factor promoter polymorphism. Cytokine 2000;12:110–9.
- Kaijzel EL, Bayley JP, van Krugten MV, Smith L, van de Linde P, Bakker AM, et al. Allele-specific quantifica-tion of tumor necrosis factor-a (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. Genes Immunol 2001;2: 135–44.
- Bayley JP, de Rooij H, van der Elsen PJ, Huizinga TW, Verweij CL. Functional analysis of linker-scan mutants spanning the -376, -308, -244, and -238 polymorphic sites of the TNF-a promoter. Cytokine 2001;14:316–23.
- Mugnier B, Balandraud N, Darque A, Roudier Ch, Roudier J, Reviron D. Polymorphism at position -308 of the tumor necrosis factor a gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003;48: 1849–52.
- Butler DM, Maini RN, Feldman M, Brennan FM. Modula-tion of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti-TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 1995;6: 225–30.
- Feldmann M, Brennan F, Paleolog E, Taylor P, Maini RN. Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action. Eur Cytokine Netw 1997;8: 297–300.